Fig. 2: Structure activity relationship (SAR) study of (+)-enantiomer-CBD derivatives using EEG recordings.
From: Carvone derived cannabidiol enantiomers as novel anticonvulsants
a Timeline of SAR, red lines denote administration of (+)-CBD derivative (20 mg*kg-1 p.o.). b Representative traces (top) and spectrograms (bottom) of EEG recordings following 20 mg*kg-1 p.o. with (+)-CBD derivatives. c–e Fast Fourier transform analysis of the EEG signal comparing (+)-CBDV (Baseline: 0.998 ± 0.0419, ( + )-CBDV: 1.196 ± 0.0419), ( + )-CBDP (Baseline: 0.996 ± 0.0463, ( + )-CBDP: 1.204 ± 0.0463), and (+)-CBD-oct (Baseline: 0.984 ± 0.0210, ( + )-CBD-oct: 1.188 ± 0.0210), to vehicle baseline. f–j Spectral analysis of (+)-CBDV (All bands n.s.). k–o. Spectral analysis of (+)-CBDP (θ Baseline: 6.149 ± 1.468, β (+)-CBDP: 0.923 ± 0.0303). p–t Spectral analysis of (+)-oct compared to baseline (δ Baseline: 4.764 ± 0.822, δ (+)-CBD-oct: 6.242 ± 1.137; θ Baseline: 5.918 ± 1.780, θ (+)-oct: 8.407 ± 1.780). All values listed are mean (or LS mean) ± standard error, p values from Two Way Repeated Measures ANOVA, with Bonferroni post hoc; or t-test. Line graphs are plotted as mean and standard error, and box plots are plotted as median, first and third quartile, and range.
